The abstract submission is now open!
Abstract submission deadlines
Deadline |
Date and time |
|---|---|
|
Tuesday, 7 January 2025, 21:00 CET (Central European Time) |
Outcome notifications
Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by early February 2025.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-March in the section “Information for Presenters”.
Abstract submission categories
- Central Nervous System (CNS)
- Digestive cancers
- Genitourinary cancers
- Gynaecological cancers
- Head and neck cancers
- Neuroendocrine and Endocrine cancers
- Public Policy and Patient Advocacy
- Research methodology
- Sarcoma
- Skin cancers and Melanomas
- Thoracic cancers
- Miscellaneous
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Sarcoma and Rare Cancers Congress 2025.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The Sarcoma and Rare Cancers Congress 2025 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including Late-breaking, will be published online in the ESMO Sarcoma and Rare Cancers Congress 2025 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
Publication schedule of accepted abstracts
Abstracts accepted for presentation during the ESMO Sarcoma and Rare Cancers Congress 2025 will be released online according to a schedule which will be available on the ESMO website in due course.
ESMO Merit Travel Grant
A restricted number of ESMO Merit Travel Grants to the ESMO Sarcoma and Rare Cancers Congress 2025 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Sarcoma and Rare Cancers Congress 2025 Scientific Committee on a competitive basis from among the accepted abstracts.